Mirum Pharmaceuticals
MIRM
73 hedge funds and large institutions have $465M invested in Mirum Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 9 closing their positions.
82% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $606K
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $405M → $465M (+$60.4M)
9% more funds holding
Funds holding: 67 → 73 (+6)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
0.36% less ownership
Funds ownership: 76.86% → 76.5% (-0.36%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.09M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$5.02M |
| 3 |
Axa
Paris,
France
|
+$3.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.04M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.45M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$5.48M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.49M |
| 4 |
SCM
Sio Capital Management
New York
|
-$3.35M |
| 5 |
DM
Deerfield Management
New York
|
-$2.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SI
76
Sofinnova Investments
Menlo Park,
California
| – | -$4.49M | -259,465 | Closed |
|
|
BCM
77
Burrage Capital Management
Boston,
Massachusetts
| – | -$3.56M | -205,866 | Closed |
|
78
Fidelity Investments
Boston,
Massachusetts
| – | -$1.98M | -114,328 | Closed |
|
|
PP
79
PDT Partners
New York
| – | -$321K | -18,546 | Closed |
|
|
RIL
80
Rothschild Investment LLC
Chicago,
Illinois
| – | -$201K | -11,600 | Closed |
|
|
E
81
Ergoteles
New York
| – | -$190K | -11,000 | Closed |
|
82
Russell Investments Group
London,
United Kingdom
| – | -$44K | -2,600 | Closed |
|
MIRM Hedge Fund Activity: Q3 2021 in Review
73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2021, worth a combined $465M — up 15% from $405M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MIRM positions and 9 closed out — a net gain of 6 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $7.09M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $6.45M sold.
- 73 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2021, up from 67 in Q2 2021.
- Funds reported $465M of Mirum Pharmaceuticals stock for Q3 2021, up 15% quarter-over-quarter.
- 15 funds opened new Mirum Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +6 holders.
- The largest Mirum Pharmaceuticals buyer in Q3 2021 was BVF Inc, an estimated $7.09M added.
- The largest Mirum Pharmaceuticals seller in Q3 2021 was Driehaus Capital Management, an estimated $6.45M sold.
Based on aggregated 13F filings for Q3 2021.